Latest period
$0.00
YoY change
-100.0%
5Y CAGR
-100.0%
Peak year (2024)
$327.34M
Latest annual
$0.00
Stock-Based Compensation history chart for Novo Nordisk (NVO) from 1990 to 2025
Latest: $0.00
Stock-Based Compensation growth chart for Novo Nordisk (NVO) from 1990 to 2025
Latest: -100.0%
Stock-Based Compensation history table for Novo Nordisk (NVO) from 1990 to 2025
| 2025 | $0.00 | -100.0% | −$327.34M | ||
| 2024 | $327.34M | +5.5% | +$17.15M | ||
| 2023 | $310.18M | +46.7% | +$98.72M | ||
| 2022 | $211.46M | +32.3% | +$51.58M | ||
| 2021 | $159.88M | +21.2% | +$27.97M | ||
| 2020 | $131.91M | +145.2% | +$78.12M | ||
| 2019 | $53.80M | -15.0% | −$9.49M | ||
| 2018 | $63.29M | +37.0% | +$17.09M | ||
| 2017 | $46.21M | -13.3% | −$7.12M | ||
| 2016 | $53.32M | -17.8% | −$11.56M | ||
| 2015 | $64.88M | +4.2% | +$2.63M | ||
| 2014 | $62.25M | -16.6% | −$12.40M | ||
| 2013 | $74.66M | +39.3% | +$21.08M | ||
| 2012 | $53.58M | — | +$53.58M | ||
| 2011 | $0.00 | — | $0.00 | ||
| 2010 | $0.00 | — | $0.00 | ||
| 2009 | $0.00 | — | $0.00 | ||
| 2008 | $0.00 | — | $0.00 | ||
| 2007 | $0.00 | — | $0.00 | ||
| 2006 | $0.00 | — | $0.00 | ||
| 2005 | $0.00 | — | $0.00 | ||
| 2004 | $0.00 | — | $0.00 | ||
| 2003 | $0.00 | — | — | ||
| 2002 | — | — | — | ||
| 2001 | — | — | — | ||
| 2000 | — | — | — | ||
| 1999 | — | — | — | ||
| 1998 | — | — | — | ||
| 1997 | — | — | — | ||
| 1996 | — | — | — | ||
| 1995 | — | — | — | ||
| 1994 | — | — | — | ||
| 1993 | — | — | — | ||
| 1992 | — | — | — | ||
| 1991 | — | — | — | ||
| 1990 | — | — | — |
- 2025$0.00-100.0%
- 2024$327.34M+5.5%
- 2023$310.18M+46.7%
- 2022$211.46M+32.3%
- 2021$159.88M+21.2%
- 2020$131.91M+145.2%
- 2019$53.80M-15.0%
- 2018$63.29M+37.0%
- 2017$46.21M-13.3%
- 2016$53.32M-17.8%
- 2015$64.88M+4.2%
- 2014$62.25M-16.6%
- 2013$74.66M+39.3%
- 2012$53.58M—
- 2011$0.00—
- 2010$0.00—
- 2009$0.00—
- 2008$0.00—
- 2007$0.00—
- 2006$0.00—
- 2005$0.00—
- 2004$0.00—
- 2003$0.00—
- 2002——
- 2001——
- 2000——
- 1999——
- 1998——
- 1997——
- 1996——
- 1995——
- 1994——
- 1993——
- 1992——
- 1991——
- 1990——
Stock-Based Compensation values are taken from Novo Nordisk's reported cash flow statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About Stock-Based Compensation at Novo Nordisk (NVO)
Stock-Based Compensation for Novo Nordisk (NVO): headline value $0.00 · YoY -100.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual stock-based compensation for Novo Nordisk (NVO) came in at 0.00 DKK – plunged 100.0% year-over-year.
Over 2020–2025 (5 years), Novo Nordisk stock-based compensation expanded at a -100.0% compound annual rate, with a net decline across the window.
The record annual stock-based compensation stands at 2.29B DKK, reached in 2024; the historical low of 0.00 DKK was recorded in 1990.
Novo Nordisk Stock-Based Compensation by Year
Novo Nordisk Stock-Based Compensation 2025: $0.00
Novo Nordisk stock-based compensation in 2025 was 0.00 DKK ($0.00), plunged 100.0% below 2024.
Novo Nordisk Stock-Based Compensation 2024: $327.34M
2024's stock-based compensation for Novo Nordisk came in at 2.29B DKK ($327.34M), grew 6.5% from 2023. This figure represents the highest annual value in the available history.
Novo Nordisk Stock-Based Compensation 2023: $310.18M
Novo Nordisk posted stock-based compensation of 2.15B DKK ($310.18M) in 2023, surged 39.6% from 2022.
Novo Nordisk Stock-Based Compensation 2022: $211.46M
In 2022, Novo Nordisk reported stock-based compensation of 1.54B DKK ($211.46M), surged 48.0% from 2021.
Novo Nordisk Stock-Based Compensation 2021: $159.88M
Novo Nordisk stock-based compensation in 2021 was 1.04B DKK ($159.88M).
See more financial history for Novo Nordisk (NVO).
Sector peers by Stock-Based Compensation
Healthcare peers of Novo Nordisk (NVO), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $310.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $310.00M
- $0.00
- $0.00
- $0.00
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation